Carcinoma hepatocelular e linfoma multicêntrico canino - tratamento com ciclofosfamida metronômica
DOI:
https://doi.org/10.22456/1679-9216.133396Palavras-chave:
antineoplastic agents, lymphosarcoma, chemotherapy, survival.Resumo
Background: Hepatocellular carcinomas (HCC) represent approximately 50% of primary liver neoplasms and can be localized or distributed throughout the parenchyma. Lymphoma is the clonal proliferation of lymphocytes, with the multicentric form being the most common in dogs. Metronomic chemotherapy consists of the administration of low-dose antineoplastic agents at short, regular intervals. However, no effective treatment for nodular or disseminated HCC nor reports of metronomic chemotherapy in dogs with lymphoma exist. Thus, this study aimed to report the use of antineoplastic therapies in 2 dogs diagnosed with inoperable nodular HCC and multicentric lymphoma.
Cases: The 1 st patient was a 16-year-old bitch mixed breed weighing 7.4 kg that was treated at the Veterinary Hospital of the Federal University of Santa Maria (HVU-UFSM). Ultrasound examination revealed nodular structures measuring approximately 1 cm throughout the hepatic parenchyma, with the largest one measuring approximately 4.48 x 3.07 cm located in the left lateral lobe. An increased uterine volume was also observed. Exploratory celiotomy showed pyometra and hepatic nodules. Liver biopsy confirmed the diagnosis of HCC. Owing to the impossibility of surgical resection, the treatment of choice was metronomic chemotherapy with cyclophosphamide at 15 mg/mm2 every 48 h with follow-up imaging and blood tests. Nine months after diagnosis, a nodular area of approximately 1.5 x 1.3 cm was identified in the greater curvature of the stomach. The patient remained clinically stable, with stable neoplasm progression. However, at
the age of 19 years, the bitch died 2 years and 5 months after the metronomic administration of cyclophosphamide, and
the causa mortis was elderliness. The 2 nd patient was a 10-year-old bitch Shih Tzu weighing 3.7 kg, referred for suspected lymphoma and also examined at the HVU-UFSM. The patient manifested with enlarged mandibular and popliteal lymph nodes and lymphocytic leukocytosis. A multicentric lymphoma was confirmed via fine-needle aspiration cytology (FNAC) and through clinical signs and blood tests. Chemotherapy treatment was initiated with the CHOP regimen, which included cyclophosphamide [200 mg/m2 ], vincristine [0.6 mg/m2 ], doxorubicin [25 mg/m2], and prednisone [5 mg/kg]. However, this regimen was not effective and changed to chlorambucil [3 mg/m2 ), VO, SID, for 4 days] and prednisone [1 mg/kg, VO, SID]. However, this protocol was not feasible due to the unavailability of the drug on the market; therefore, metronomic chemotherapy was initiated. The bitch received cyclophosphamide 15 mg/m2 every 48 h, showing clinical improvement
in the lymphocytic leukocytosis. Chronic anemia, weight loss, leukemia, and chronic kidney disease occurred as compli-
cations and were treated accordingly. The bitch lived for 3 years and 6 months after the diagnosis and eventually died due to years of treatment and worsening general condition due to the acquired complications.
Discussion: Veterinary Medicine is faced with several challenges in designing effective metronomic chemotherapy regi-
mens, including the selection of appropriate drugs and the establishment of effective doses. Both patients in this report
received cyclophosphamide [15 mg/m 2, every 48 h]. In human medicine, metronomic chemotherapy is considered a safe
and potentially useful treatment, which was observed in the reported patients since it presented few side effects and an
increased survival period of 880 days in the patient with HCC and 1,275 days in the patient with multicentric lymphoma.
This regimen can be considered for inoperable tumors and in cases of refractory to conventional regimens.
Keywords: antineoplastic agents, lymphosarcoma, chemotherapy, survival.
Título: Carcinoma hepatocelular e linfoma multicêntrico canino - tratamento com ciclofosfamida metronômica
Descritores: antineoplásicos, linfossarcoma, quimioterapia, sobrevida
Downloads
Referências
Abensur H. 2010. Deficiência de ferro na doença renal crônica. Revista Brasileira de Hematologia e Hemoterapia. 32(2): 95-98. DOI: https://doi.org/10.1590/S1516-84842010005000047
Biller B., Berg J., Garrett L., Ruslander D., Wearing R., Abbott B., Patel M., Smith D. & Bryan C. 2016. 2016 AAHA Oncology Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association. 52(4):181-204. DOI: https://doi.org/10.5326/JAAHA-MS-6570
Bonamigo R. 2022. Intervalos de referência para exames laboratoriais de cães da região de Santa Maria. Rio Grande do Sul, Brasil. 44f. Dissertação (Mestrado em Medicina Veterinária) – Programa de Pós-Graduação em Medicina Veterinária, Universidade Federal de Santa Maria.
Calazans S.G., Daleck C.R., Nardi A.B. 2017. Linfomas. In: Dalek C.R. & Nardi A.B. (Eds) Oncologia de cães e gatos. 2.ed. Rio de Janeiro: Roca, pp. 633-648.
Cápua M.L.B., Coleta F.E.D., Canesin A.P.N.M., Godoy A.V., Calazans S.G., Miotto M.R., Daleck, C.R. & Santana A.E. 2011. Linfoma canino: clínica, hematologia e tratamento com o protocolo de Madison-Wisconsin. Ciência Rural. 41(7): 1245-1251. DOI: https://doi.org/10.1590/S0103-84782011005000090
Couto C.G. 2015. Linfoma. In: Nelson R.W. & Couto C.G. (Eds) Medicina interna de pequenos animais. Rio de Janeiro: Elsevier, pp.1160- 1174.
Denies S., Cicchelero L., De Rooster H., Daminet S., Polis I., Van de Maele I. & Sanders N.N. 2017. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients. Veterinary and Comparative Oncology. 15(2), 594–605. DOI: https://doi.org/10.1111/vco.12203
Furian M., Meneghetti M.M., Montanha F.P. 2011. Carcinoma hepatocelular - Relato de caso. Revista Científica Eletrônica Da Faculdade de Medicina Veterinária e Zootecnia de Garça. 9(16): 1-8.
Harper A., Blackwood L. 2017. Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer‐bearing dogs: a retrospective study. Journal of Small Animal Practice. 58(4): 227-230. DOI: https://doi.org/10.1111/jsap.12635
Mangieri J. 2017. Síndromes Paraneoplásicas em cães e gatos. In: Dalek C.R. & Nardi A.B. (Eds) Oncologia de cães e gatos. Rio de Janeiro: Roca, pp. 325-338.
Michishita M., Ezaki S., Ogihara K., Naya Y., Azakami D., Nakagawa T., Sasaki N., Arai T., Shida T. & Takahashi K. 2014. Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line. Research in Veterinary Science. 96(2): 315-322. DOI: https://doi.org/10.1016/j.rvsc.2014.01.004
Proença A.R.S.G. 2009. Linfoma maligno multicêntrico canino. 99f. Dissertação (Mestrado em Medicina Veterinária) – Faculdade de Medicina Veterinária, Universidade Técnica de Lisboa.
Rodigheri S.M. & Nardi A.B. 2017. Quimioterapia Metronômica. In: Dalek C.R. & Nardi A.B. (Eds) Oncologia de cães e gatos. Rio de Janeiro: Roca, pp. 243-248.
Terra E.M., Ferreira T.M.M.R. & Rodrigues L. 2017. Neoplasias hepáticas. In: Dalek C.R. & Nardi A.B. (Eds) Oncologia de cães e gatos. Rio de Janeiro: Roca, pp. 415-421.
Torimura T., Iwamoto H., Nakamura T., Koga H., Ueno T., Kerbel R.S. & Sata M. 2013. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Translational oncology. 6(5): 511–519. DOI: https://doi.org/10.1593/tlo.13481
Vail D.M. & Young K.M. 2007. Hematopoietic Tumors. In: Withrow S.J. & MacEwen’s E.G. (Eds) Small Animal Clinical Oncology. Philadelphia: Wiley Blackwell, pp. 699-733. DOI: https://doi.org/10.1016/B978-072160558-6.50034-4
Valli V.E., Bienzle D. & Meuten, D.J. 2017. Tumors of the Hemolymphatic System. In: Meuten, D.J. (Ed) Tumors in Domestic Animals. Usa: Wiley Blackwell, pp. 203-221. DOI: https://doi.org/10.1002/9781119181200.ch7
Weisse C., Clifford C.A., Holt D. & Solomon J.A. 2002. Percutaneous arterial embolization and chemoembolization for treatment of benign and malignant tumors in three dogs and a goat. Journal of the American Veterinary Medical Association. 221(10): 1430–1419. DOI: https://doi.org/10.2460/javma.2002.221.1430
Arquivos adicionais
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Franciéli Mallmann Pozzobon, Rainer da Silva Reinstein, Paula Cristina Basso, Maurício Veloso Brun, Daniel Curvello de Mendonça Müller

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
This journal provides open access to all of its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Such access is associated with increased readership and increased citation of an author's work. For more information on this approach, see the Public Knowledge Project and Directory of Open Access Journals.
We define open access journals as journals that use a funding model that does not charge readers or their institutions for access. From the BOAI definition of "open access" we take the right of users to "read, download, copy, distribute, print, search, or link to the full texts of these articles" as mandatory for a journal to be included in the directory.
La Red y Portal Iberoamericano de Revistas Científicas de Veterinaria de Libre Acceso reúne a las principales publicaciones científicas editadas en España, Portugal, Latino América y otros países del ámbito latino